期刊文献+

青霉属真菌P-9生物转化罗汉果总苷的研究

Dtermination of Transformation Products in Microbial Transformation of Cucubitane Triterpene Glycosides from Momordica grosvenori by Penicillium sp P-9 by HPLC
下载PDF
导出
摘要 采用青霉属真菌P-9对罗汉果总苷进行生物转化,主要转化产物A、B、C经熔点、比旋度、质谱(MS)、红外光谱(IR)和核磁共振(NMR)波谱分析,鉴定为:A为罗汉果醇-24-O-β-D-葡萄吡喃糖基-(1→2)β-D-葡萄吡喃糖苷;B为罗汉果醇-3-O-β-葡萄吡喃糖基-24O-β-D-葡萄吡喃糖基-(1→2)1B-D-葡萄吡喃糖苷;C为11-酮-罗汉果醇-3-O-β-D-葡萄吡喃糖基-24—O-β-D.葡萄吡喃糖基-(1→2)18.D-葡萄吡喃糖苷,A、B、C三种化合物均未见文献报道。采用高效液相色谱法,以CIS-ODS为色谱柱,乙腈(A)-水(B)作为流动相进行梯度洗脱,检测波长为:203nm,柱温:30℃,流速:1mL/min,进样量:10灿,测得在底物加量为0.5%,28℃,220r/min下摇瓶培养120h,主要产物A、B、C的含量最高分别为1.006、0.293、0.025mg/mL。在选定的色谱条件下转化产物A、B线性范围良好,转化产物A、B的平均加样回收率分别为99.3%.97.8%,RSD分别为1.9%、1.2%。 We found a penicillium sp J-9 which can transform Momordica grosvenori into products A, B and C. Three products were identified by melting point,MS,IR,NMR. The method of HPLC for the transformation products A 、B and C. ZW&A C18 (250 × 4.60 mm ,5μm)column was used as the stationry phase. The mobile phase was acotonitrile: water, the UV detection wavelength was 203 nm,the column temperature was 30 ℃ ,the flow rate was 1.0 mL/min,the injection volume was 10 μL. The transformation last 120 h under 28 ℃ ,220r/min and substrate at a concertration of 0.5%. The three kinds of products had changeable contents in different time. Results show that the content of products A and B indicates a good linearity under these conditions with average recoveries of (99.3 ± 1.12 ) % and ( 97.8 ± 1.68 ) % and RSDs of 1.9% and 1.2%.
机构地区 上海师范大学
出处 《天然产物研究与开发》 CAS CSCD 北大核心 2014年第A02期299-304,共6页 Natural Product Research and Development
关键词 高效液相色谱 微生物转化 罗汉果总苷 转化产物A、 B、 C HPLC microbial transformation mogrosides transformation products A, B and C
  • 相关文献

参考文献3

二级参考文献16

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005,55(2):74-108.
  • 2Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008 [J]. CA Cancer J Clin, 2008,58(2):71-96.
  • 3Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy [ J ]. Nat Rev Cancer, 2003,3 (7) : 502 -516.
  • 4Biagi JJ, Eisenhauer EA. Systemic treatment policies in ovarian cancer: the next 10 years [J]. Int J Gynecol Cancer, 2003,13(2) :231-240.
  • 5Chen JC, Chiu MH, Nie RL, et al. Cucurbitacins and cucurbitane glycosides : structures and biological activities [J]. Nat Prod Rep, 2005,22 (3) : 386-399.
  • 6Duncan KL, Duncan MD, Alley MC, et al. Cucurbitacin E- induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells [Jl. Biochem Pharmacol, 1996,52 (10) : 1553-1560.
  • 7Sun J, Blaskovich MA, Jove R, et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity [J]. Oncogene, 2005,24(20) : 3236-3245.
  • 8Sun J, Blaskovich MA, Jove R, et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity [J]. Oncogene, 2005,24(20) : 3236-3245.
  • 9Clericuzio M, Mella M, Vita-Finzi P, et al. Cucurbitane triterpenoids from Leucopaxillus gentianeus [J ]. Nat Prod, 2004,67 ( 11 ) : 1823-1828.
  • 10Tannin-Spitz T, Grossman S, Dovrat S, et al. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells [J]. Biochem Pharmacol, 2007,73 ( 1 ) : 56-67.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部